

REMARKS

Currently Claims 1-33 are pending, claims 34 and 35 having been canceled. Claims 1, 4-6, 8-11, 13, 14, 16-20, 22, 23, 25, and 27-32 have been amended to place them in form appropriate to US practice, to reduce the filing fee by removing multiple dependencies, and/or to correct typographical errors, and have not been made for reasons substantially related to patentability.


The specification has been amended to include a reference to related applications/claim of priority to the corresponding PCT application and foreign filed application.

Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Applicants respectfully submit that the present application is in condition for examination and respectfully request the early consideration thereof and the issuance of a Notice of Allowance forthwith.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted:


J. Michael Strickland
Attorney for Applicants
Reg. No. 47,115

Date: May 3, 2005
GlaxoSmithKline Inc.
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Tel. (919) 483-9024
Fax: (919) 483-7988